Intercept Rallies Ahead Of NASH Readout
Perhaps in anticipation of NASH data, shares of Intercept (ICPT) continue to rally and, just recently, broke strong technical resistance:
Introduction
Intercept's obeticholic acid should see phase 3 NASH data this quarter. Although analysts think the drug is likely to procure positive results, the path towards marketization, assuming there is other competition, may not be easy given the drug's overt side effects (itching, increases in bad cholesterol) and a black-box warning (liver damage, but only when a patient doesn't take as prescribed).
Background
Obeticholic acid (marketed as